TAT-Gap19 TFA is primarily used in research focused on studying the role of connexin-43 hemichannels in cellular communication and their involvement in various physiological and pathological processes. It is a peptide inhibitor that specifically targets these hemichannels, making it valuable in investigating conditions such as cardiac arrhythmias, ischemia-reperfusion injury, and inflammatory diseases. Researchers utilize it to explore potential therapeutic strategies by modulating connexin-43 activity, which could lead to advancements in treating heart diseases, brain injuries, and other conditions linked to aberrant hemichannel function. Its application is largely confined to experimental studies in cellular and animal models, providing insights into the mechanisms of cell signaling and tissue damage.